WE.SPEED.
We love being in the lead! ARENSIA has once again achieved a significant milestone by enrolling the first patient globally, this time in a complex multiple sclerosis trial.
In just 2 months, ARENSIA Clinic in Kyiv, Ukraine, randomized 18 patients with relapsing-remitting multiple sclerosis, making it the first clinic worldwide to include patients among the planned 60 sites. Additionally, ARENSIA Clinic in Chisinau, Moldova, contributed to this progress by dosing an additional 7 patients during the same period. This trial involves challenging procedures like complex PreDose cognitive assessments and an intensive PK schedule, utilizing recombinant humanized immunoglobulin (Ig) G1 monoclonal antibody.
ARENSIA's commitment to prioritizing neuroscience research remains strong across all its clinics.
In addition to outstanding patient enrollment, ARENSIA has set quick start-up timelines worldwide, with approval timelines of 10 working days in Moldova and 35 days in Ukraine.
We are proud to offer our patients early access to innovative therapies and support our Sponsors with exceptional quality and efficiency. This achievement reflects the dedication of the ARENSIA teams.
19.03.2024